Fig. 5.

HER2-CRB improves HER2-TDB in vivo activity. A JimT-1 tumor volume growth over-time in NSG mice (left) with or without adoptive transfer of human PBMCs treated with HER2-TDB alone, HER2-CRB alone or in combination (combo). Individual mouse tumor volumes are represented in right panel. Slash represents a mouse death due to health conditions. (B, left) Change in tumor volumes of the Fo5 tumor model. Mice were treated with mHER2-TDB, mHER2-CRB or in combination (combo). Vehicle treatment was used as a negative control. (Right) Individual tumor volumes at day 4 and day 7 from. Mann–Whitney test used for statistical analysis; *p, ≤ 0.05; **, p ≤ 0.01